{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 5 List of study procedures for AECOPD visits', 'Type of contact', 'AECOPD Visit', 'End of AECOPD phone call(s)', 'Time point', 'at least every 2 weeks as of', 'within 96 hours of onset', 'AECOPD visit until AECOPD', 'symptoms', 'has resolvedi', 'Record date of visit', 'Physical examination', 'Urine Pregnancy Test', 'Chest X-rays/pneumonia confirmationi', 'Confirm AECOPD and record its start date', 'Record current medication for AECOPD', 'Record healthcare resource utilisation', 'Record additional COPD treatments prescribed by', 'primary and secondary care physicians', 'Sputum samplingk', 'HRQOL questionnaire:', 'CAT', 'O', 'Record AECOPD severitym', '.', 'Record AECOPD end date', 'Record Adverse Events (AEs)*/ related to study', 'participation', 'Record serious adverse events (SAEs) related to', 'study participation', '^ Refer to Table 10 for description of which AE/SAEs are collected in this study.', 'Section 6.4 Detailed description of study procedure', 'Sputucm sampling at sub-sections 6.4.1.14 - 6.4.2.15 - 6.4.3.9:', 'Remaining DTT-sputum will be aliquoted as such and/or further diluted in STGG. These', 'samples will be kept at - -70/80\u00b0C until shipment to GSK or GSK designated lab for', 'testing.', 'Section 6.4.2.6 Pregnancy test', 'Female subjects of childbearing potential are to have a urine pregnancy test prior to', 'any study procedure. Note: The urine pregnancy test must be performed even if the', 'subject is menstruating at the time of the study visit.', 'Section 6.4.2.10 Record current medication for COPD', 'At each study visit/contact, the investigator should question the subject about any', 'medications taken. administered for treatment of COPD.', 'All medications administered for treatment of COPD will be recorded in the eCRF.', '19-OCT-2018', '116', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 6.5.3 Laboratory assays', 'Table 8 Microbiology', 'Further bacterial pathogens identification', 'Viral pathogens identification', 'System', 'Component', 'Method', 'Scale', 'Laboratory', 'Quality assessment', 'Fresh sputum', 'Please refer to SPM and/or', 'Gram staining', 'Qualitative/', 'Investigator institution or', 'Central Laboratory Manual', 'semi-', 'GSK designated', 'for components tested', 'quantitative', 'laboratory', 'Bacterial pathogen identification', 'Fresh sputum', 'Respiratory bacterial', 'Standard', 'Qualitative', \"Investigator's institution\", 'pathogens', 'bacteriological', 'and/or at a laboratory', '(including H. influenzae,', 'culture and', 'Semi-', 'designated by GSK', 'S. pneumoniae,', 'standard', 'quantitative', 'Biologicals', 'M. catarrhalis, S. aureus,', 'identification', 'P. aeruginosa,', 'methods including', 'K. pneumoniae and A.', 'semi-quantitative', 'baumannii)', 'culture', 'H. influenzae', 'H. influenzae species', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'confirmation and when', 'techniques such', 'laboratory* or designated', 'H. influenzae culture', 'possible Hi/NTHi', 'as differentiation', 'laboratory', 'plates', 'differentiation', 'PCR', 'Sample collection for', 'potential further', 'characterisation', 'Stored sputum', 'Respiratory bacterial', 'Multiplex PCR', 'Qualitative', 'GSK Biologicals', 'pathogens', 'and/ or quant', 'laboratory or', '(including H. influenzae,', 'itative', 'designated laboratory', 'S. pneumoniae,', 'M. catarrhalis, S. aureus and', 'P. aeruginosa,', 'Streptococcus pyogenes))', 'Viral pathogen identification', 'Stored sputum', 'Respiratory viral pathogens', 'Multiplex-PCR', 'Qualitative', 'GSK Biologicals', '(including RSV,', 'laboratory * or', 'parainfluenza virus,', 'designated laboratory', 'enterovirus/ HRV,', 'metapneumovirus, influenza', 'virus, adenovirus, bocavirus', 'and coronavirus)', 'Respiratory viral pathogens', 'RT-PCR', 'Quantitative', 'GSK Biologicals', '(such as HRV)', 'laboratory* or designated', 'laboratory', 'Stored frozen sputum samples (in DTT supplemented with skim milk, tryptone, glucose,', 'and glycerine [STGG] medium) might be collected when possible for potential assay', 'development validation purpose.', '19-OCT-2018', '117', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}